RHHBY Roche Holding Ltd ADR (Sponsored)

34.73
+0.17  (+1%)
Previous Close 34.55
Open 34.56
Price To Book 8.73
Market Cap 237323583855
Shares 6,833,388,536
Volume 649,094
Short Ratio
Av. Daily Volume 1,556,359

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2019.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
BLA filing announced February 5, 2019.
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
PDUFA date under priority review August 18, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
PDUFA date under priority review March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data released July 1, 2018. PFS endpoint met. PFS =7.2 vs. 5.5 months. HR 0.80.
Tecentriq plus nab-paclitaxe - IMpassion 130
First-line triple negative breast cancer (TNBC)
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data released at ASCO June 2018.
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
PDUFA date March 12, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 data due 2019.
Tecentriq
Urothelial cancer
Phase 3 data due 2019.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data due 2019.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
PDUFA date 4Q 2019.
Fedratinib
Myelofibrosis
Phase 3 data due 2019.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 data due 2019.
Venclexta BELLINI
Multiple myeloma
PDUFA date under priority review August 19, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
  2. Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
  3. Biogen stock down 1.2% after downgrade by Stifel
  4. Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
  5. 2 Pharma Stocks in the Middle of an Oncology Sales Explosion
  6. FDA grants Priority Review to Roche's personalised medicine entrectinib
  7. FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma
  8. FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
  9. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
  10. Yahoo Finance's exclusive extended interview with DoubleLine CEO Jeffrey Gundlach
  11. Jeffrey Gundlach talks millennials, national debt, and the race for 2020
  12. Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates
  13. Yahoo Finance's exclusive interview with DoubleLine CEO Jeffrey Gundlach
  14. Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
  15. Ascendis Pharma Files IND for Hypoparathyroidism Candidate
  16. Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript
  17. Bristol-Myers' Sprycel Gets European Nod for Label Expansion
  18. Aurora earnings show concern for pot stocks
  19. ImmunoGen Still Waiting to Take Its Leap "Forward"
  20. A Flu Drug Was Called ‘Silver Bullet,’ but Some Doctors Prescribe Caution